8-Chloro-cAMP (8-Cl-cAMP) is a novel agent that is able to inhibit the growth of a wide variety of
cancer cell types in vitro and in vivo and, at doses devoid of toxicity, to achieve plasma concentrations in
cancer patients in a range effective for
cancer cell growth inhibition. In this study, we have demonstrated that
8-Cl-cAMP, at a dose causing mild or no growth inhibition, synergistically increased the growth-inhibitory effect of
paclitaxel or
cisplatin in a wide series of cell lines including human breast, lung, ovary, colon, and head
carcinomas and
melanoma. A similar effect was also observed with another
taxane,
docetaxel, and with the
platinum-derivative
carboplatin.
8-Cl-cAMP also markedly enhanced apoptotic cell death induced by each cytotoxic
drug. A cooperative antitumor effect was also observed in vivo, because treatment with
paclitaxel followed by
8-Cl-cAMP markedly inhibited the growth of GEO human
colon cancer xenografts as compared to
paclitaxel alone without signs of toxicity. These data demonstrate that
8-Cl-cAMP synergistically increases the antiproliferative activity of
taxanes and
platinum-derived compounds and provide a rationale to use
8-Cl-cAMP in combination with
taxanes and
platinum-derived compounds.